Every 8-K that Ocuphire Pharma, Inc. (OCUP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow OCUP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OCUP filings page.
Opus Genetics, Inc. reported that it has appointed Robert Gagnon as Chief Financial Officer and principal accounting officer, effective September 2, 2025. He will receive an annual base salary of $465,000 and will be eligible for an annual performance bonus of up to 45% of his base salary.
As part of his package, Opus Genetics will grant Mr. Gagnon a stock option for 250,000 shares of common stock and a separate award for 200,000 shares, each vesting over four years under the company’s 2021 Inducement Plan. The company states there are no arrangements with other persons relating to his selection, no family relationships with current leadership, and no related-party transactions requiring disclosure. Mr. Gagnon brings prior CFO and senior finance experience from several life sciences and healthcare companies.
Opus Genetics, Inc. disclosed a private placement financing in which it agreed to issue and sell 3,138,338 shares of common stock, raising approximately $3.5 million in gross proceeds. The transaction closed on August 25, 2025 and involved certain investors led by board chair Cam Gallagher, who invested $1.0 million, alongside lead independent director Sean Ainsworth and other participants.
The company plans to use the net proceeds to expedite manufacturing process development, including scaling up clinical and commercial production and testing to secure sufficient cGMP material for its gene therapy candidates OPGx-LCA5 and OPGx-BEST1. The shares were sold without underwriting discounts or commissions and were issued in reliance on private offering exemptions under Section 4(a)(2) and/or Regulation D of the Securities Act.
Opus Genetics, Inc. reported that on August 13, 2025 it issued a press release announcing its financial results for the second quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1 to this Current Report and the company also furnished a Cover Page Interactive Data File (Inline XBRL) as Exhibit 104.1. The filing states the information in Item 2.02 and Exhibit 99.1 is furnished, not filed, and therefore is not subject to Section 18 of the Exchange Act or incorporated by reference except by specific reference in a later filing. The report shows Opus Genetics is a Delaware corporation and lists its common stock trading under the ticker IRD on Nasdaq. The document is signed by Dr. George Magrath, Chief Executive Officer.
Opus Genetics (Nasdaq:OCUP) filed a Form 8-K disclosing topline results from VEGA-3, its second pivotal Phase 3 trial of Phentolamine Ophthalmic Solution 0.75 % for presbyopia. Numerical efficacy and safety data were not included, but management deemed the readout material and will host a webcast on June 26, 2025 at 8:00 a.m. ET to discuss the findings and give a corporate update.
The filing reiterates prior guidance that cash on hand should fund operations into 2H FY 2026, suggesting no immediate financing need. Exhibit 99.1 contains the full press release; no new contracts, financings, or governance changes were reported. Forward-looking-statement disclaimers reference previously disclosed risk factors.